In combination with a 5-HT3 receptor antagonist and a corticosteroid, EMEND can be used in a wide range of patients receiving chemotherapy.
EMEND, in combination with other antiemetic agents, is indicated for prevention of:
- Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin.
- Nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
Selected Important Risk Information
EMEND, when administered orally, is a moderate cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitor. Because fosaprepitant is rapidly converted to aprepitant, neither drug should be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions.
Before prescribing EMEND or EMEND for Injection, please read the Prescribing Information. The Patient Information also is available.
For information about Merck products or services, please call 866-448-7590. The Merck National Service Center will be pleased to assist you Monday through Friday from 8 AM to 7 PM ET.
